TrialMedical oncology (Northwood, London, England)2017

Activity of cabazitaxel in patients with metastatic castration-resistant prostate cancer after treatment with single or dual regimens of novel androgen receptor-targeting agents.

Yukari Bando et al.PubMed ↗Publisher ↗

No numbers read from the abstract.